文献速递产科母胎医学

妊娠早期单步普遍巨细胞病毒筛查与伐昔洛韦预防:高血清流行率环境下的成本-效用分析

Single-Step Universal First-Trimester Cytomegalovirus Screening and Valacyclovir Prophylaxis in Pregnancy: A Cost-Utility Analysis in a High Seroprevalence Setting.
PubMed 文献 · Prenat Diagn · 2025-07-08

在高血清流行率环境下,对10万名孕妇的假设队列进行支付者视角成本-效用分析,比较妊娠早期单步普遍巨细胞病毒血清学筛查联合伐昔洛韦预防垂直传播与常规超声导向检测。普遍筛查策略的ICER为125,864美元(170,087新加坡元)/QALY,可预防约54例先天性CMV感染、18例症状性感染及17例感音神经性听力损失和认知障碍。作者认为尽管绝对ICER较高,但与常见产前筛查方法相比具有优势。

要点

  • 普遍筛查ICER为125,864美元(170,087新加坡元)/QALY。
  • 每10万名筛查母亲可预防约54例先天性CMV感染。
  • 每10万名筛查母亲可预防18例症状性感染及17例SNHL和认知障碍。

核心结论

  • 普遍筛查的ICER绝对值较高,但与常见产前筛查方法(如中风险21三体女性的早孕期无创产前检测)的ICER相比具有优势。
  • 普遍筛查有潜力避免出生时及5岁时的儿童疾病负担。

研究设计与样本

  • 支付者视角成本-效用分析,假设10万名孕妇队列,时间跨度9个月足月妊娠及子代终生。
  • 采用决策树和马尔可夫模型,评估预防先天性CMV后遗症所获得的质量调整生命年(QALY)与普遍筛查和伐昔洛韦预防成本。

主要发现

  • 普遍筛查策略相比常规超声导向检测的ICER为125,864美元(170,087新加坡元)/QALY。
  • 每10万名筛查母亲可预防约54例先天性CMV感染、18例症状性感染及17例5岁前感音神经性听力损失和认知障碍。

关键数值与推荐

  • 影响成本效果的主要因素包括:伐昔洛韦预防垂直CMV传播的效果、妊娠期原发CMV感染患病率、围受孕期感染后症状性先天性CMV的概率、血清学检测成本。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the cost-effectiveness of first trimester single-step universal cytomegalovirus (CMV) serological screening with valacyclovir as vertical transmission prophylaxis versus routine ultrasound-directed testing. METHODS: A payer perspective cost-utility analysis was conducted on a hypothetical population of 100,000 pregnant women for a time horizon of 9 month of full-term pregnancy and the lifetime of children. Using a decision-tree and Markov model, we assessed quality-adjusted life years (QALYs) gained by preventing congenital CMV (cCMV) sequelae against the costs of universal screening and valacyclovir prophylaxis. RESULTS: The ICER for universal screening strategy was USD125,864 (SGD170,087)/QALY-gained compared to routine ultrasound-directed testing. It prevented approximately 54 cCMV infections, 18 cases of symptomatic infections, and 17 cases of sensorineural hearing loss (SNHL) and cognitive impairment by age of 5 per 100,000 mothers screened. The primary factors influencing cost-effectiveness include the effectiveness of VCV in preventing vertical CMV transmission, the prevalence of primary CMV infection during pregnancy, the probability of symptomatic congenital CMV following periconceptional infection, and the cost of serological testing. CONCLUSIONS: Although the ICER of universal CMV screening appears high in absolute terms, it compares favorably with ICER of commonly offered antenatal screening methods such as first trimester non-invasive prenatal testing for women at intermediate risk of Trisomy 21. Universal screening has the potential for averting childhood morbidity at birth and by 5-years-old. Important variables influencing the ICER include the effectiveness of valacyclovir in preventing vertical transmission, prevalence of primary CMV infection, probability of symptomatic cCMV after periconception primary infection and cost of serology tests.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Lim ZZ, Ong C, Chan CY, et al. Single-Step Universal First-Trimester Cytomegalovirus Screening and Valacyclovir Prophylaxis in Pregnancy: A Cost-Utility Analysis in a High Seroprevalence Setting. Prenat Diagn. 2025. PMID: 40627409. doi:10.1002/pd.6848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。